Home » News » Conference Coverage » IASLC » WCLC 2022
WCLC 2022
Sublobar resection is noninferior to a full lobectomy in patients with carefully staged cT1aN0 non-small cell lung cancer, new research suggests.
Recent exposure to systemic treatment does not increase the risk of 30-day mortality in patients with thoracic cancers and COVID-19.
Long-term cumulative exposure to air pollution should be included in assessments of lung cancer risk, according to researchers.
Consent forms could be improved by a patient-centric addendum highlighting key points, a study suggests.
Adding pembrolizumab to chemotherapy can improve survival in extensive-stage small cell lung cancer, a phase 3 study suggests.
Researchers found that 77% of patients had moderate to severe sexual dysfunction.
Advanced disease at diagnosis is more likely among younger patients with non-small cell lung cancer, according to a new study.
COVID-19 vaccination does not appear to prevent SARS-CoV-2 infection in patients with lung cancer, but it may prevent severe COVID-19.
Sugemalimab consolidation improved progression-free survival, when compared with placebo, in patients with unresectable, stage III non-small cell lung cancer.
Adding nivolumab to neoadjuvant platinum-based chemotherapy can improve survival in patients with stage IIIA-B non-small cell lung cancer, new data suggest.
Load More
Open
Next post in WCLC 2022
Close
Close more info about Sublobar Resection Should Be New Standard Care for Certain Patients With NSCLC
Loading...
Close more info about Sublobar Resection Should Be New Standard Care for Certain Patients With NSCLC
Loading...